Please assess the completion status of the following clinical trial:

Trial Title: Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing cardiac surgery requiring cardiopulmonary bypass (CPB)~* Heparin resistant according to this definition: initial activated clotting time (ACT) after an intravenous loading dose of heparin (300 u/kg) is less than 480 seconds~Exclusion criteria:~* current use of one or more of these medications:~  * warfarin (within 3 days of surgery);~ * streptokinase;~ * tissue plasminogen activator;~ * abciximab,~ * eptifibatide,~ * tirofiban or~ * clopidogrel.~* known hypersensitivity to goat or goat milk proteins,~* patients with pre-existing coagulopathy defined as a history of bleeding or laboratory bleeding disorder (e.g., von Willebrand disease, platelet disorder) and~* patients receiving direct thrombin inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Recombinant antithrombin (rhAT) (Type: EXPERIMENTAL): Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.

Based on this trial design, predict the completion outcome and termination type (if applicable).